Celonic to Help Produce 100 Million CureVac Vaccine Doses
German biopharmaceutical developer CureVac has teamed with Switzerland-based Celonic Group to help manufacture more than 100 million doses of CureVac’s messenger RNA-based COVID-19 vaccine CVnCoV.
Production will occur at Celonic’s plant in Heidelberg, Germany, with Celonic expected to manufacture 50 million of the doses before year’s end. CureVac said its entire European manufacturing network is expected to produce up to 300 million doses this year.
CureVac previously negotiated an advance purchase agreement with the EU to supply up to 405 million doses of its vaccine, contingent upon regulatory approval.
The European Medicines Agency is currently evaluating CVnCoV under a rolling review, but the data from CureVac’s phase 2b/3 trial, which is enrolling 35,000 participants, will not be available for several months to support a conditional marketing authorization.